

PRIOR AUTHORIZATION REQUEST FORM

AKYNZEO® IV

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance: University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:	HCPCS Code:	

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Akynzeo® (fosaprepitant/palonosetron) IV

Dosing/Frequency: _____

Questions	Yes	No	Comments/Notes
1. Is this request for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic intravenous chemotherapy?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Is the request for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic intravenous chemotherapy? Documentation must show previous treatment failure, intolerance, contraindication, to a steroid + 5HT3 RA + olanzapine OR clinical reasoning as to why NK-1 RA is needed.	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Has the member tried and failed aprepitant and fosaprepitant in combination with palonosetron?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Is the request for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide (AC) chemotherapy? Documentation must show medical necessity.	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

REAUTHORIZATION

1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does documentation show the therapy was effective with a positive clinical response to therapy?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.

Additional information:
Physician Signature:

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request. ****

Policy: PHARM- M028
Origination Date: 08/27/2020
Reviewed/Revised Date: 05/18/2022
Next Review Date: 05/18/2023
Current Effective Date: 06/01/2022

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.